Erythema multiforme (EM)

[Anonymous]

Erythema multiforme (EM) is an acute inflammatory disease of the skin and mucous membranes that causes a variety of skin lesions—hence the name “multiforme.” The oral lesions, typically inflammation accompanied by rapidly rupturing vesicles and bullae, are often an important component of the clinical picture and are occasionally the only component.

Erythema multiforme may occur once or recur, and it should be considered in the diagnosis of multiple acute oral ulcers whether or not there is a history of similar lesions. There is also a rare chronic form of EM. EM has several clinical presentations: a milder self-limiting form and severe life-threatening forms that may present as either Stevens-Johnson syndrome or toxic epidermal necrolysis (TEN).

ETIOLOGY
EM is an immune-mediated disease that may be initiated either by deposition of immune complexes in the superficial microvasculature of skin and mucosa, or cell-mediated immunity. Other health care workers have detected elevated levels of immune complexes and decreased complement in fluid samples taken from vesicles.
The most common triggers for episodes of EM are herpes simplex virus and drug reactions. The drugs most frequently associated with EM reactions are oxycam nonsteroidal antiinflammatory
drugs (NSAIDs); sulfonamides; anticonvulsants such as carbamazepine, phenobarbital, and phenytoin; trimethoprim-sulfonamide combinations, allopurinol, and penicillin.

The relationship of HSV to episodes of EM has been known for over 50 years, but improved diagnostic techniques, including polymerase chain reaction (PCR) and in situ hybridization have demonstrated that herpes-associated EM is a common form of the disease, accounting for at least 20 to 40% of the cases of single episodes of EM and approximately 80% of recurrent EM. Herpes antigens have been demonstrated in the skin and immunocomplexes obtained from patients with EM. Many investigators now believe that the major cause of EM is a cellular immune response to HSV antigens deposited in keratinocytes of the skin and mucosa.46 The tendency to develop mucous membrane lesions during episodes of herpes-associated EM appears
to be genetically determined and related to specific human leukocyte antigen (HLA) types.

CLINICAL MANIFESTATIONS
General Findings. EM is seen most frequently in children and young adults and is rare after age 50 years. It has an acute or even an explosive onset; generalized symptoms such as fever and malaise appear in severe cases. A patient may be asymptomatic and in less than 24 hours have extensive lesions of the skin and mucosa. EM simplex is a self-limiting form of the disease and is characterized by macules and papules 0.5 to 2 cm in diameter, appearing in a symmetric distribution. The most common cutaneous areas involved are the hands, feet, and extensor surfaces of the elbows and knees. The face and neck are commonly involved, but only severe cases affect the trunk. Typical skin lesions of EM may be nonspecific macules, papules, and vesicles. More typical skin lesions contain petechiae in the center of the lesion. The pathognomonic lesion is the target or iris lesion, which consists of a central bulla or pale clearing area surrounded by edema and bands of erythema .

Oral Findings. Oral lesions commonly appear along with skin lesions in approximately 70% of EM patients. In some cases, oral lesions are the predominant or single site of disease. When the oral lesions predominate and no target lesions are present on the skin, EM must be differentiated
from other causes of acute multiple ulcers, especially primary herpes simplex infection. This distinction is important because corticosteroids may be the treatment of choice in EM, but they are specifically contraindicated in primary herpes simplex infections.When there are no skin lesions and the oral lesions are mild, diagnosis may be difficult and is usually made by exclusion of other diseases. Cytologic smears and virus isolation may be done to eliminate the possibility of primary herpes infection. Biopsy may be performed when acute pemphigus is suspected. The histologic picture of oral EM is not considered specific, but the finding of a perivascular lymphocytic infiltrate and epithelial edema and hyperplasia is considered suggestive of EM.
The diagnosis is made on the basis of the total clinical picture, including the rapid onset of lesions. The oral lesions start as bullae on an erythematous base, but intact bullae are rarely seen by the clinician because they break rapidly into irregular ulcers.Viral lesions are small, round, symmetric, and shallow, but EM lesions are larger, irregular, deeper, and often bleed. Lesions may occur anywhere on the oral mucosa with EM, but involvement of the lips is especially prominent, and gingival involvement is rare.This is an important criterion for distinguishing EM from primary herpes simplex infection, in which generalized gingival involvement is characteristic.

TREATMENT
Mild cases of oral EM may be treated with supportive measures only, including topical anesthetic mouthwashes and a soft or liquid diet. Moderate to severe oral EM may be treated with short course of systemic corticosteroids in patients without significant contraindications to their use. Systemic corticosteroids should only be used by clinicians familiar with the side effects, and, in each case, potential benefits should be carefully weighed against potential risks. Young children treated with systemic steroids for EM appear to have a higher rate of complications than do adults, particularly gastrointestinal bleeding and secondary infections. Adults treated with short-term systemic steroids have a low rate of complications and a shorter course of EM. The protein-wasting and adrenal-suppressive effects of systemic steroids are not significant when used short-term, and the clinical course of the disease may be shortened.An initial dose of 30 mg/d to 50 mg/d of prednisone or methylprednisolone for several days, which is then tapered, is helpful in shortening the healing time of EM, particularly when therapy is started early in the course of the disease. It should be noted that the efficacy of this treatment has not been proven by controlled clinical trials and is controversial. Patients with severe cases of recurrent EM have been treated with dapsone, azathioprine, levamisole, or thalidomide. EM triggered by progesterone, also referred to as autoimmune progesterone dermatitis and stomatitis, has been treated successfully with tamoxifen. In resistant cases, oophorectomy has been necessary to cure the disorder. Antiherpes drugs such as acyclovir or valacyclovir can be effective in preventing susceptible patients from developing herpes- associated EM, if the drug is administered at the onset of the recurrent HSV lesion. Prophylactic use of antiherpes drugs is effective in preventing frequent recurrent episodes of HSV associated EM.

        

[sushantpatel_doc]

images

        

[Anonymous]

DIFFERENTIAL DIAGNOSIS
ERYTHEMA MULTIFORME
Interface vacuolar change with numerous necrotic keratinocytes

Diagnostic Pearls

* Erythematous targetoid lesions
* Lichenoid interface dermatitis with vacuolar change and intraepidermal necrotic keratinocytes.
* Subepidermal vesiculation with papillary dermal edema progressing to bullae formation.

LICHEN PLANUS
Hyperkeratosis, hypergranulosis, irregular acanthosis

Diagnostic Pearls

* Polygonal, planar, pruritic, purplish papules, present in 4th to 6th decade, more commen in women
* Compact ortho and hyperkeratosis, wedge-shaped hypergranulosis centered around acrosyringium
* Band-like infiltrate of lymphocytes (rare, if any plasma cells); necrotic keratinocytes (civatte bodies) are limited to lower epidermis

LUPUS ERYTHEMATOSIS
Discoid lupus erythemtous: Epidermal thinning, hyperkeratosis, superficial and deep dermal perivascular and peri adnexal infiltrate involving subcutaneous tissue.

Diagnostic Pearls

* Erythematous, annular scaly plaques on face, upper chest and extremities
* Superficial and deep dermal perivascular and periadnexal infiltrate may involve subcutaneous tissue
* Dermal mucin deposition

        

[Author]

Posts